News by subject: Clinical Study

Datacubed Health, a leading provider of innovative technology solutions for clinical research, is proud to announce its partnership with renowned medical practitioner Eugene Lipov, M.D. in a pioneering study focused on the extent of physiologic...

Triple Hair Group Inc. ("Triple Hair" or the "Company"), a company specializing in the development of innovative treatments for alopecia, is pleased to announce that it has received positive results from various preclinical safety studies on its...

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML PopulationsTP53MUT CR/CRh = 20% ? RASMUT...

Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster...

Algernon Pharmaceuticals Inc.  (the "Company" or "Algernon") a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9th American Cough Conference (ACC)...

Ractigen Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of novel oligonucleotide therapeutics, today announced the dosing of its first patient in the Company's First in Human (FIH) clinical...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third...

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global marketsLotus Pharmaceuticals will acquire...

Spectral Medical Inc. ("Spectral" or the "Company") , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company's follow-on study designed to build on...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company's U.S. Food & Drug...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the...

ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo Cytisinicline demonstrated 6x increase in odds of...

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular degeneration (wAMD), and/or diabetic macular edema...

Data demonstrated that AAV vectors expressing engineered immunomodulatory interferon (IFN) cytokine payloads led to: Rapid and selective reduction in tumor size in high-grade glioma (HGG) organoidsTumor regression and significantly prolonged survival...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company's U.S. Food & Drug...

Salipro Biotech AB and DyNAbind GmbH, two leading biotech companies, announced today the achievement of a key milestone from their collaboration aimed to revolutionize drug discovery against difficult-to-drug targets. The collaboration combines the...

? Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ? ? Doublet of Tuspetinib and Venetoclax Dosing Underway for...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative...

XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce completion of a positive and constructive Type D...

Ceapro Inc. ("Ceapro" or...

PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a specialty pharmaceutical company, today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration ("FDA") for KETARXtm (ketamine) for the treatment for...

Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1 Findings highlight impact on patient adherence of early onset of improvement with topical psoriasis medications1...

IntelGenx Corp. (the "Company" or "IntelGenx") today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC ("Xiromed"), has received a Complete Response Letter ("CRL") from the U.S. Food and Drug...

TransCode Therapeutics, Inc. , a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has received written approval from the Dana Farber Cancer Institute...

Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...

Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODYtm...

Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending human healthspan, is pleased to announce that its lead compound exhibited protective effects in a preclinical model...

Sirona Biochem Corp. ("Sirona") is pleased to announce that the clinical trial results, for novel anti-aging compound TFC-1326, have exceeded even high expectations on key criteria. The trial, which was completed by a leading contract...

BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis...

Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction...

Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today...

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will be presenting five abstracts at the upcoming 2023 American...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...

Rakovina Therapeutics Inc. (the "Company") today announced the presentation of new data describing the progress of the Company's kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando,...

PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the Clinical Psychedelic Lab at Monash University's upcoming Phase 2 Clinical Trial. "Australia is rapidly becoming one of the most exciting locations for MDMA...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company's U.S. Food & Drug...

? ZW191 demonstrates strong responses in FR?-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles? ZW171 induced potent preferential killing of cancer cells and potential to mitigate risk of...

Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced positive results in EUPHAS-2, an...

Today, Arch Biopartners Inc., ("Arch" or the "Company") , a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg...

IntelGenx Corp. (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's RIZAFILM® VersaFilm® 505(b)(2) new drug application (NDA) for the...

Lifeist Wellness Inc. ("Lifeist" or the "Company") , a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that its U.S. biosciences subsidiary...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the...

Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive six-month data from the Company's Phase IIa clinical trial...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated...

- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts - Continued tumor reduction and complete regression of one of three metastatic lesions in...

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein (CSF t-tau and p-tau181) in the cerebral...

PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a specialty pharmaceutical company, today announced an update on the Type C meeting with the U.S. Food and Drug Administration ("FDA") for advancing KETARXtm (ketamine) towards Phase 3...

In Cohort 3, after 4 weeks of once-daily 100 mg dosing with the investigational, oral covalent menin inhibitor, BMF-219, 89% of patients achieved a reduction in A1c, 78% of patients achieved at least a 0.5% reduction in A1c, and 56% achieved at least...

Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered...